

June 30, 2023

Adenosine Injection Allocation Update

Dear Valued Customer,

Fresenius Kabi Canada would like to inform you that, due to the shortage of Dipyridamole, we will be making limited quantities of our **Adenosine Injection 3 mg/mL SD Vial 2 mL** and **Adenosine Injection 3 mg/mL prefilled syringe 2 mL** available in excess of our 100% historical monthly demand.

To ensure equitable distribution of the limited inventory, we have calculated allocations by province based on historical Dipyridamole sales and have created hospital-level allocations based on guidance provided by hospital GPOs. We recognize that some hospitals that require this product may not have any sales history with us. Therefore, we have asked hospital GPOs to work with their members to allocate the product where it is most needed.

As a result, our contract customers will continue to receive **100% of their historical monthly allocation**. **Additionally, some hospitals may receive additional inventory based on guidance from their hospital GPO.**

DIN	Fresenius Kabi Product Code	MDP Product Code	McKesson Product Code	Product Description	July & August Allocations
02267659	C605102	937071	192880	Adenosine Injection 3 mg/mL SD Vial 2 mL	100% plus potentially additional inventory based on GPO guidance.
02457474	K051002	970852	115670	Adenosine Injection 3 mg/mL prefilled syringe 2 mL	100% plus potentially additional inventory based on GPO guidance.

We recognize the difficulties and inconvenience that you may encounter, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact your sales representative.

Sincerely,



Joseph Le
Senior Manager, Commercial Operations & Analytics
joseph.le@fresenius-kabi.com